Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2018-04-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 7 pages 1.1MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated April 30, 2018, providing an Appendix 4C quarterly report for the March 2018 quarter. Appendix 4C is a standard quarterly cash flow report required by the Australian Securities Exchange (ASX) Listing Rule 4.7B. The document includes detailed cash flow statements, operational updates, and compliance statements. It is a quarterly report containing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is over 11,000 characters, indicating it is the report itself, not just an announcement of publication. Hence, the correct classification is IR with high confidence. Q3 2018
2018-04-29 English
Amended Appendix 4C - Cash balance at 31/3 $3.904M 8 pages 1.2MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated April 30, 2018, providing an Appendix 4C quarterly report for the March 2018 quarter. It includes detailed cash flow statements, operational updates, and compliance statements related to Listing Rule 4.7B. The content focuses on quarterly financial and operational data, including cash receipts, payments, and estimated cash outflows for the next quarter. The document is over 12,000 characters, indicating it is a substantive report rather than a brief announcement. The Appendix 4C is a recognized quarterly report format for entities listed on the ASX, which aligns with the definition of an Interim / Quarterly Report (IR) as it contains actual financial statements and substantive financial data for a period shorter than a full fiscal year. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q3 2018
2018-04-29 English
Notice of Annual General Meeting/Proxy Form 10 pages 149.6KB
AGM Information Classification · 100% confidence The document is titled as a Notice of Annual General Meeting (AGM) for Lifespot Health Limited. It includes details about the meeting date, location, agenda items such as consideration of financial statements and reports for the year ended 31 December 2017, adoption of the remuneration report, and re-election of directors. It also contains proxy voting instructions and explanatory statements related to the AGM. The document does not contain the actual financial statements or reports but refers shareholders to the Annual Report available online. The content is consistent with materials distributed to shareholders prior to an AGM to inform them about the meeting and the business to be conducted. Therefore, this document fits the category of AGM Information (AGM-R).
2018-04-22 English
Final Director's Interest Notice 2 pages 64.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the cessation of a director and the director's interests in securities, with no securities held. This is a report of personal share transactions or holdings by a company director. The document length is short and focused solely on director's dealings, with no financial statements or other report content. Therefore, it fits the category of Director's Dealing (DIRS).
2018-04-16 English
Initial Director's Interest Notice 2 pages 58.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, with no securities held. This is a report of personal share transactions or interests by a company director. The document length is short and focused solely on director's dealings, matching the definition of Director's Dealing (DIRS).
2018-04-16 English
Update on development of unique cannabis vaporizer 2 pages 225.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated April 13, 2018, from Lifespot Health Ltd. It discusses the progress and commercialization plans of a unique cannabis vaporizer product. The content focuses on product development milestones, integration with software infrastructure, cooperation discussions, and market potential. There are no financial statements, regulatory certifications, voting results, or management changes reported. The document is a corporate announcement about product development and business updates rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a report publication announcement or a certification. The best fitting category is a general Regulatory Filing (RNS) as it is a regulatory announcement made to the stock exchange about business progress and plans.
2018-04-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.